Clinical trials: Asthma Patients
Asthma
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
The primary purpose was to evaluate the efficacy of SKP FlutiForm HFA MDI compared to placebo or fluticasone and formoterol administered concurrently or alone in asthma patients.
- Trial name
- NCT00830102
- Testing
- fluticasone propionate, formoterol fumarate
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 64 people
- Sponsor
- SkyePharma AG
Asthma
Non-interventional Retrospective Multicenter Study of Patients With Bronchial Asthma During a Routine Visit to Out of Patients' Clinics
To assess asthma control in Russian patients according to the new criteria provided in the international guidelines and identify pharmacological approaches that provide a higher level of overall asthma control
- Trial name
- NIKA (NCT01273363)
- Where
- 12 sites in Russia
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Asthma
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway…
- Trial name
- NCT02712047
- Testing
- Fluticasone furoate (FF) (100 mcg), Vilanterol (VI) (25 mcg)
- Where
- New Zealand
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients
The present study is designed to collect data on real world experience on use of Medrol in acute asthma in Indian patients.
- Trial name
- NCT00971893
- Testing
- Oral Methylprednisolone Tablets
- Sponsor
- Pfizer
Moderate to Severe Persistent Asthma
Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
This study will evaluate the efficacy, safety of two dose levels of CBP-201 in patients with moderate to severe persistent asthma with Type 2 inflammation.
- Trial name
- NCT04773678
- Testing
- CBP-201
- Where
- 76 sites in United States, China and 3 more
- Volunteers
- 322 people
- Sponsor
- Connect Biopharm LLC
Severe Eosinophilic Asthma
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
This is a prospective, multi-center, single-arm Phase 3b study designed to evaluate the potential benefit to patients if benralizumab treatment could enable reduction in asthma maintenance controllers while allowing patients to…
- Trial name
- STEP (NCT06465485)
- Testing
- Benralizumab
- Where
- 74 sites in China
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Severe Asthma
ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab
This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical…
- Trial name
- ANANKE (NCT04272463)
- Testing
- No intervention
- Where
- 18 sites in Italy
- Volunteers
- 217 people
- Sponsor
- AstraZeneca
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-1 (NCT05274750)
- Testing
- Depemokimab (GSK3511294)
- Where
- 105 sites in United States, Argentina and 9 more
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Asthma
Study in Patients With Asthma
The purpose of this study is to determine the most safe and effective dose of the investigational drug in comparison with a control drug and placebo.
- Trial name
- NCT00215410
- Testing
- Formoterol Fumarate
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- Dey
Asthma
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days.
- Trial name
- NCT00549744
- Testing
- GSK256066
- Where
- 3 sites in New Zealand, South Africa
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Asthma
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
The primary objective of the study is to characterize the efficacy of reslizumab treatment, at a dosage of 3.0 milligrams per kilogram (mg/kg) every 4 weeks for a total of 4 doses, in improving pulmonary function in relation to…
- Trial name
- NCT01508936
- Testing
- Reslizumab
- Where
- 66 sites in United States
- Volunteers
- 511 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
The number of people with of asthma and allergy is still increasing and a large number of patients still do not have their asthma well controlled.
- Trial name
- NCT02427165
- Testing
- RPL554, Salbutamol
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Asthma
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.
- Trial name
- NCT02260492
- Testing
- OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)
- Where
- 47 sites in United States
- Volunteers
- 879 people
- Sponsor
- Oriel Therapeutics
Asthma
A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy of lebrikizumab compared with placebo, as measured by the ability of participants to achieve lower daily doses of…
- Trial name
- NCT01987492
- Testing
- Lebrikizumab
- Where
- 71 sites in United States, Australia and 14 more
- Volunteers
- 230 people
- Sponsor
- Hoffmann-La Roche
Asthma
A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients
The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised…
- Trial name
- NCT00331292
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Asthma
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691).
- Trial name
- NCT02134028
- Testing
- Dupilumab
- Where
- 365 sites in United States, Argentina and 25 more
- Volunteers
- 2,282 people
- Sponsor
- Sanofi
Asthma
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320)…
- Trial name
- NCT02571777
- Testing
- QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320
- Where
- 403 sites in Argentina, Austria and 39 more
- Volunteers
- 3,092 people
- Sponsor
- Novartis Pharmaceuticals
Bronchiolitis
Dexamethasone in the Treatment of Bronchiolitis in Patients With Either Eczema and or Family History of Asthma
The investigators hypothesized that oral Dexamethasone in addition to nebulized Salbutamol will improve the Bronchiolitis Clinical Severity Score,duration of treatment in the short stay unit,need for hospitalization and…
- Trial name
- #9105 (NCT01065272)
- Testing
- Dexamethasone
- Where
- Qatar
- Volunteers
- 200 people
- Sponsor
- Hamad Medical Corporation
Severe Asthma
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS).
- Trial name
- SAIL-B (NCT07218172)
- Where
- Israel
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Healthy, Asthma
A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways
A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.
- Trial name
- NCT01310322
- Testing
- AZD5423
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca